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The complete nucleotide sequence of the RSV cpts-248/404 live attenuated vaccine candidate was determined from
cloned cDNA and was compared to that of the RSV A2/HEK7 wild-type, cold-passaged cp-RSV, and cpts-248 virus, which
constitute the series of progenitor viruses. RSV cpts-248/404 is more attenuated and more temperature sensitive (ts) (shut-
off temperature 367) than its cpts-248 parent virus (shut-off temperature 387) and is currently being evaluated in phase I
clinical trials in humans. Our ultimate goal is to identify the genetic basis for the host range attenuation phenotype exhibited
by cp-RSV (i.e., efficient replication in tissue culture but decreased replication in chimpanzees and humans) and for the ts
and attenuation phenotypes of its chemically mutagenized derivatives, cpts-248 and cpts-248/404. Compared with its cpts-
248 parent, the cpts-248/404 virus possesses an amino acid change in the polymerase (L) protein and a single nucleotide
substitution in the M2 gene start sequence. In total, the cpts-248/404 mutant differs from its wild-type RSV A2/HEK7
progenitor in seven amino acids [four in the polymerase (L) protein, two in the fusion (F) glycoprotein, and one in the (N)
nucleoprotein] and one nucleotide difference in the M2 gene start sequence. Heterogeneity at nucleotide position 4 (G or
C, negative sense, compared to G in the RSV A2/HEK7 progenitor) in the leader region of vRNA developed during passage
of the cpts-248/404 in tissue culture. Biologically cloned derivatives of RSV cpts-248/404 virus that differed at position 4
possessed the same level of temperature sensitivity and exhibited the same level of replication in the upper and lower
respiratory tract of mice, suggesting that heterogeneity at this position is not clinically relevant. The determination of the
nucleotide sequence of the cpts-248/404 virus will allow evaluation of the stability of the eight mutations that are associated
with the attenuation phenotype during vaccine production and following replication in humans. q 1996 Academic Press, Inc.
RSV, a single-stranded negative-sense RNA virus, is a disease enhancement during subsequent wild-type in-
fection (2). Our objective is to produce a live attenuated,member of the Paramyxoviridae family. The RSV genome
bivalent subgroup A and B RSV vaccine to protect againstconsists of a linear RNA molecule with 15,222 nucleo-
the severe lower respiratory tract disease caused bytides (1). RSV is the most important cause of viral bronchi-
these viruses.olitis and pneumonia in infants and children (1). Several
A series of attenuated mutant viruses has been gener-strategies for immunization against this virus have been
ated by random chemical mutagenesis of a partially at-studied including peptide vaccines, protein subunit vac-
tenuated, cold-passaged (cp) parent virus, cp-RSV. Thecines, recombinant vectored vaccines, and live attenu-
cp-RSV mutant acquired non-temperature-sensitive hostated RSV vaccines. Recently developed live attenuated
range attenuating mutations during 52 passages at lowRSV strains remain attractive vaccine candidates be-
temperature in bovine tissue culture (3–5). cp-RSV wascause of their superior immunogenicity, induction of mu-
also slightly more restricted in replication in mice andcosal immune responses, and lack of association with
chimpanzees (6). Chemical mutagenesis of the cp-RSV
virus with 5-fluorouracil yielded a more temperature-sen-
sitive (ts) derivative (cpts-248) with a 387 shut-off temper-1 The nucleotide sequence data reported in this manuscript for cpts-
248/404 have been submitted to the GenBank nucleotide sequence ature of plaque formation in vitro. Although the cpts-248
database and have been assigned the accession number U63644. mutant was demonstrated to be partially attenuated and
2 To whom correspondence and reprint requests should be ad- genetically stable, it retained residual reactogenicity in
dressed.
chimpanzees, causing rhinorrhea and an intermediate3 Current address: Division of Pediatric Infectious Diseases, Depart-
level of replication in the lower respiratory tract (6). Thement of Pediatrics, Vanderbilt University Medical Center, D-7235 MCN,
Nashville, TN 37232-2581. cpts-248 mutant was subjected to another round of
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chemical mutagenesis with 5-fluorouracil to generate a RSV A2/HEK7, the cpts-248/404 mutant differs in seven
amino acids (four in L, two in F, and one in N) and onenew series of mutants that had acquired lower shut-off
temperatures and greater restriction of replication in vivo. nucleotide substitution in the start signal of the M2 gene
(Table 1).One such mutant, cpts-248/404, was more ts (367 shut-
off temperature) and more restricted in its replication in The RNA used for the initial sequence analysis of the
3*-end leader was extracted from a RSV cpts-248/404mice and chimpanzees (7). This cpts-248/404 vaccine
candidate is currently being evaluated for safety, immu- suspension prepared after six passages beyond biologi-
cal cloning. Of 12 independent cDNA clones generatednogenicity, and genetic stability in human trials. The spe-
cific goal of the present study is to initiate studies to from this preparation of RNA, 25% had C (negative sense)
at nucleotide 4, while 75% retained the wild-type nucleo-determine the genetic basis of attenuation of this live
virus vaccine candidate by complete nucleotide se- tide G. Six cDNA clones were generated from the 3*-
end of vRNA prepared after only three passages beyondquence analysis of its genome, as has been reported
previously for its RSV A2/HEK7, cp-RSV, and cpts-248 biological cloning, and all were determined to be G at
nucleotide 4. This finding, as well as the presence of Gprogenitors (5, 8).
Nine overlapping cDNA clones representing the com- at position 4 on the progenitor of cpts-248/404, indicates
that heterogenicity developed at this nucleotide positionplete genome of mutant virus cpts-248/404 were gener-
ated by RT-PCR of total infected cell or virion-derived during passage of the cpts-248/404 virus in Vero cell
culture. We next sought to determine if this heterogeneityRNA (vRNA) (5, 8). This RNA was isolated from a cpts-
248/404 suspension which had been passaged six times had an identifiable effect on the ts or attenuation pheno-
types. The virus suspension at passage level six wasin cell monolayer cultures following biological cloning by
plaque purification. The complete nucleotide sequence biologically cloned and 17 plaque populations were sub-
jected to three serial plaque purifications and sequenceof each cDNA clone was determined by automated DNA
sequencing at the NCI Frederick Cancer Research and analysis of their 3*-ends. Sixteen of the cloned viruses
were G and 1 was C at nucleotide 4. The temperatureDevelopment Center (Frederick, MD) using the Taq DYE
Deoxy Terminator cycle sequencing kit (ABI, Foster City, sensitivity of two of the cpts-248/404 clones that differed
at position 4 was assayed by determining the efficiencyCA) on an M13 random library constructed for each cDNA
plasmid insert from sonicated DNA. Clones containing of plaque formation in tissue culture at various tempera-
tures. A shut-off temperature of 367 was observed forthe 3*-end leader were prepared by polyadenylation of
purified vRNA followed by RT-PCR, and clones containing both clones (Table 2). Likewise, a difference was not
observed for the replication of these viral clones in eitherthe 5*-end trailer were prepared from vRNA by RT, termi-
nal transferase tailing, and PCR (5, 8). For the purpose the nasal turbinates or lungs of mice (Student’s t test, P
 0.05) (Table 2).of sequence verification, cDNA clones were derived from
a second, independent RT-PCR for those regions at It was interesting to find that the acquisition of the ts
phenotype by the cpts-248/404 virus was associated withwhich the sequence of cpts-248/404 differed from that of
cp-RSV (5) and cpts-248 (8). Clones of the 3*-end leader, an amino acid substitution in the polymerase protein
since such changes in polymerase proteins of several5*-trailer, and these second cDNA clones were manually
sequenced by the dideoxynucleotide chain termination respiratory viruses have been identified frequently in ts
mutants and in vaccine candidates bearing ts mutationsmethod using Sequenase 2.0 (USB, Cleveland, OH).
It was previously found that RSV cpts-248 differed from (8–14). Specifically, ts mutants of parainfluenza virus
type 3 (9–11), influenza virus (12–14), and RSV (8) pos-its cp-RSV parent virus by only one nucleotide change
at position 10989 (ArT), in positive sense, corresponding sess a ts phenotype associated with an amino acid sub-
stitution in a polymerase protein. The frequency of atten-to a change from glutamine to leucine at amino acid 831
of the polymerase (L) protein (8) (Table 1). In the present uating mutations localized to the polymerase gene may
simply reflect the large size of the gene, over 40% of thestudy it was found that the cpts-248/404 mutant pos-
sesses two nucleotide differences from its cpts-248 par- genome in the case of RSV. The findings from the present
study in the context of the previous studies suggest thatent virus, one at nucleotide 12046 (TrA) in the L gene
and one at nucleotide 7605 (TrC) in the transcription the nucleotide change in the L gene at position 12046
of cpts-248/404 may be responsible for the increasedstart signal of the M2 gene (Table 1). The nucleotide
substitution in the L gene resulted in a predicted aspartic ts of this mutant. Neither of the polymerase (L) protein
mutations in cpts-248 or cpts-248/404 are within the pro-acid to glutamic acid change at amino acid 1183 in the
polymerase (L) protein. Thus after two independent posed polymerase (15) or ATP-binding motifs (16).
Sequence analysis revealed that cpts-248/404 alsorounds of mutagenesis of cp-RSV, the cpts-248/404 virus
acquired two nucleotide changes in the L gene (corre- possesses a nucleotide substitution at position 7605
which is located at position 9 of the transcription genesponding to two amino acids substitutions) and one nu-
cleotide change in the transcription start signal of the start signal of the M2 gene. It is possible that this nucleo-
tide substitution in the M2 gene-start sequence, ratherM2 gene (Table 1). Compared to its wild-type progenitor,
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TABLE 1
Nucleotide Sequence Differences among cp-RSV, cpts-248, cpts-248/404 Mutant Viruses
Nucleotide and amino acidc
Nucleotide Amino acid RSV
positiona positionb Gene A2/HEK7 cp-RSV cpts-248 cpts-248/404
1938 267 N G (val) A (ile)d A (ile) A (ile)
6313 218 F A (glu) C (ala) C (ala) C (ala)
7228 523 F C (thr) T (ile) T (ile) T (ile)
7605 Gene Start T T T C
(M2)e
9453 319 L G (cys) A (tyr) A (tyr) A (tyr)
10989 831 L A (gln) A (gln) T (leu) T (leu)
12046 1183 L T (asp) T (asp) T (asp) A (glu)
13565 1690 L C (his) T (tyr) T (tyr) T (tyr)
a Numbered from 3*-end of negative sense (viral) RNA.
b Numbered for each individual protein starting from the AUG initiation codon.
c Nucleotide designations are given in the positive sense. Boxes indicate the nucleotide changes between cp-RSV and RSV A2/HEK7 wild-type,
cpts-248 and cp-RSV, or cpts-248/404 and cpts-248 viruses.
d cp-RSV consists of two populations. One shows a nucleotide change at position 1938 (G r A) resulting in a valine to isoleucine substitution,
another population contains the same nucleotide (G) as the RSV A2/HEK7 wild-type virus. Virus with A at 1938 was the immediate parent of cpts-
248.
e The parental M2 gene start sequence is (positive-sense): 5*-GGGGCAAATA, and the substituted position is underlined.
than the change in the polymerase protein indicated the relative contribution of the L and M2 gene mutations
to the ts and attenuation phenotypes by evaluation of theabove, could have been responsible for the increased
temperature-sensitivity and attenuation manifested by phenotypes of mutants that possess a single mutation
using viruses rescued from RSV cDNAs (21).the cpts-248/404 mutant. Mutations in the noncoding reg-
ulatory regions of other viruses have previously been Heterogeneity developed at position 4 of the leader
region of cpts-248/404 following passage in Vero cellshown to specify the ts and attenuation phenotypes. Spe-
cifically, nucleotide deletion, insertion, or substitution in monolayer culture. It is reasonable to suggest that nucle-
otide 4 of the early passage, biologically cloned cpts-the noncoding region specify the ts or attenuation pheno-
type of poliovirus vaccine or other picornaviruses (17– 248/404 virus was G since this was the predominant
nucleotide in populations of cloned 3*-end cDNAs and20). Importantly, it should now be possible to determine
TABLE 2
Efficiency of Plaque Formation in HEp-2 Cells and Replication in BALB/c Mice of RSV cpts-248/404 and Its 4C Variant
Virus titer (log10 PFU/g { SE)
Virus titer (log10 PFU/ml) at the indicated temperaturea in miceb
Shut-off Nasal
Virus 32 36 37 38 39 temperature turbinates Lungs
RSV A2 6.3 6.3 6.0 6.2 6.4 40 4.7 { 0.09 5.3 { 0.08
248/404-4Gc 7.0 1.7 1.7 1.7 1.7 36 2.3 { 0.19 2.2 { 0.14
248/404-4Cd 6.3 1.7 1.7 1.7 1.7 36 2.3 { 0.12 1.9 { 0.12
a Efficiency of plaque formation of RSV cpts-248/404 and its 4C variant was obtained by infecting monolayers of HEp-2 cells under semisolid
overlay and incubating at the indicated temperatures for 5 days in temperature-controlled water baths.
b Groups of 6 mice each were administered 106.0 PFU of the indicated virus intranasally in a 0.1 ml inoculum on Day 0, then sacrificed on Day
4 and assayed for virus titer. The titer of viruses in specimens obtained from the lungs and nasal turbinates of infected BALB/c mice was determined
by plaque titration at 327. SE, standard error.
c cpts-248/404 virus with the wild-type nucleotide G (negative sense) at position 4 of the 3*-end leader region.
d cpts-248/404 virus with G r C change (negative sense) at position 4 of 3*-end leader region.
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